Pathway Genomics Corporation Appoints Former Cedars-Sinai Medical Center Chair Of Medicine Glenn D. Braunstein, M.D., As Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics Corporation, a forward-thinking big data healthcare company and global precision medicine clinical laboratory, has announced that endocrinologist Dr. Glenn D. Braunstein is the company's new Chief Medical Officer. Dr. Braunstein takes on the role after serving on Pathway Genomics' Strategic Advisory Board. With a special interest in pharmacogenomics, Dr. Braunstein's first priority will be Pathway Genomics' pharmacogenomic testing menu.

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.